Peter Duncan Neuroscience homepage Neuroinflammation Group HIV Neurosciences Group Clinical Trials Group

Neurodegenerative Diseases Group: Prof Gilles Guillemin, Ph.D. Chai Kiat (Edwin) Lim, Ph.D

Prof Guillemin’s team is one of the world’s leading research groups studying neuroactive (toxic or protective or immunomodulator) metabolites derived from tryptophan metabolism and their involvement in neurodegenerative diseases.

Over the last two decades, in collaboration with Prof Brew, he demonstrated the importance of this pathway in Multiple Sclerosis, Alzheimer's disease, and amyotrophic lateral sclerosis. These results have opened promising research avenues, which are being translated into important new prognostic and therapeutic strategies.

Through their important international and national collaborative network, Prof Guillemin and his research team have extended their research to other diseases such as Parkinson’s disease, suicide, depression, autism, schizophrenia breast cancers and brain tumours.

Prof Guillemin work encompasses the:

  • Involvement of quinolinic acid and other tryptophan catabolites in the pathogenesis of neurodegenerative diseases including Motor Neurone Disease (MND), Alzheimer’s disease. Parkinson’s disease, Multiple Sclerosis.
  • Roles of the kynurenine pathway in the persistence and metastasis of breast cancer, brain tumour.
  • Identification of Biomarkers for the prognostic of amyotrophic lateral sclerosis, Alzheimer’s disease. Parkinson’s disease and Multiple Sclerosis.
  • Identification of environmental factors associated with neurodegenerative diseases.
  • Neuroprotective effects of Natural compounds for neurodegenerative diseases.

 

Selected Publications

  1. Braidy N, Rossez H, Lim CK, Jugder BE, Brew B, Guillemin G. Characterization of The Kynurenine Pathway in CD8+ Human Primary Monocyte Derived Dendritic Cells. Neurotox Res 2016 Aug 10.1007/s12640-016-9657-x
  2. Tan V, Lee J, Lovejoy D, Braidy N, Rowe D, Brew BJ, Guillemin GJ. Implications of the neurotoxin quinolinic acid in the neuropathogenesis of amyotrophic lateral sclerosis.Neuropharmacology, 2016
  3. Lim CK, Fernández-Gomez FJ, Braidy N, Estrada C, Costa C, Costa S, Bessede A, Fernandez-Villalba E, Zinger A, Herrero MT, Guillemin GJ. Involvement of the kynurenine pathway in the pathogenesis of Parkinson's disease. Prog Neurobiol. 2016 doi.org/10.1016/j.pneurobio.2015.12.009
  4. Lovelace MD, Varney B, Sundaram G, Lennon MJ, Lim CK, Jacobs K, Guillemin GJ, Brew BJ. Recent evidence for an expanded role of the kynurenine pathway of tryptophan metabolism in neurological diseases. Neuropharmacology. 2016 Mar 16. 10.1016/j.neuropharm.2016.03.024.
  5. Castellano-González G, Pichaud N, Ballard JW, Bessede A, Marcal H, Guillemin GJ. Epigallocatechin-3-gallate induces oxidative phosphorylation by activating cytochrome c oxidase in human cultured neurons and astrocytes. Oncotarget. 2016 Feb 16;7(7):7426-40.
  6. Adams S, Teo C, McDonald K, Zinger A, Bustamante S, Lim C, Sundaram G, Braidy N, Brew B, Guillemin G. Involvement of the Kynurenine Pathway in Human Glioma Pathophysiology. PLoS One 2014 Nov 21;9(11):e112945
  7. Heng B, Lim CK, Lovejoy DB, Bessede A, Gluch L, Guillemin GJ. Understanding the role of the kynurenine pathway in human breast cancer immunobiology. Oncotarget. 2016 Feb 9;7(6):6506-20.
  8. Bessede A, Gargaro M, ..., Guillemin GJ, et.al.... F, Puccetti P. Aryl hydrocarbon receptor control of a disease tolerance defence pathway. NATURE. 2014 511:184-90.
  9. Vidal C, Li W, Santner-Nanan B, Gunaratnam K, Lim CK, Guillemin GJ, Ball HJ, Hunt NH, Nanan R, Duque G. The Kynurenine Pathway of Tryptophan Degradation is Activated During Osteoblastogenesis. Stem Cell. 2014 doi: 10.1002/stem.1836

 

Neuro4

 For additional information and student opportunities, see Dr. Guillemin's Website